 | | Vol. 11.01 – 11 January, 2023 |
| |
|
|
| In human senescent cells, the authors found that HERVK, the most recently integrated human endogenous retroviruses, were unlocked to transcribe viral genes and produce retrovirus-like particles.
[Cell] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| One or two doses of a modified vaccinia virus Ankara vector expressing the SARS-CoV-2 spike protein conferred full protection against SARS-CoV-2 cerebral infection in a murine model, preventing virus replication in all areas of the brain and its associated damage.
[Nature Neuroscience] |
|
|
|
| Scientists used a multiomic approach to evaluate cellular and soluble immune mediator responses of patients enrolled in a Phase II placebo-controlled randomized clinical trial for Fostamatinib, a spleen tyrosine kinase inhibitor.
[Science Advances] |
|
|
|
| The authors addressed the need for predictions of vaccine effectiveness over time by building a mathematical framework to account for vaccination-induced immunity.
[Proceedings Of The National Academy Of Sciences Of The United States Of America] |
|
|
|
| The participants were randomly assigned with 1:1 ratio to receive a booster dose of NVSI-06-09 or BBIBP-CorV. The primary outcomes were immunogenicity and safety against severe acute SARS-CoV-2 Omicron variant, and the exploratory outcome was cross-immunogenicity against other circulating strains.
[Signal Transduction And Targeted Therapy] |
|
|
|
| Investigators used bead-based arrays and flow cytometry to measure binding of antibodies to spike proteins and receptor-binding domains (RBDs) from variants of concern in 12,000 serum samples. Effects of sera on RBD-ACE2 interactions were measured as a proxy for neutralizing antibodies.
[Npj Vaccines] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Researchers applied single-cell transcriptomics to investigate macrophage functional diversity during persistent S. enterica serovar Typhimurium infection in mice.
[Science Advances] |
|
|
|
| Scientists carried out a genome-wide CRISPR-Cas9 guide RNA screen and identified tyrosine protein kinase receptor UFO (AXL) as a proteinaceous receptor for parvovirus B19 infection of human erythroid progenitor cells.
[Science Advances] |
|
|
|
| The authors used monocyte-derived macrophages as a model to better understand the role of HIV-1 Nef, Vpu, and Env on CD4 downregulation in this cell type, and studied how this impacts Env conformation and susceptibility to antibody-dependent cellular cytotoxicity.
[Cell Reports] |
|
|
|
| Scientists showed that P. aeruginosa upregulated azurin secretion in response to increasing numbers of and proximity to cancer cells. Conversely, cancer cells upregulated aldolase A secretion in response to increasing proximity to P. aeruginosa.
[Communications Biology] |
|  |
|
|
|
| Investigators review the state of the art in phage therapy, covering biological mechanisms, clinical applications, remaining challenges, and future directions involving naturally occurring and genetically modified or synthetic phages.
[Cell] |
|
|
|
| Scientists synthesize the current understanding of the cellular and molecular determinants of mammalian antifungal immunity, focusing on observations that show promise for informing risk stratification, prognosis, prophylaxis and therapies to combat life-threatening fungal infections in vulnerable patient populations.
[Nature Reviews Immunology] |
|
|
|
| The authors discuss evidence of natural killer (NK) cell responses to different viruses, ongoing clinical efforts to treat such infections with NK cell products, and review platforms to generate NK cell products.
[Science Translational Medicine] |
|
|
|
|
| The Australian Patent is expected to grant claims relating to RECCE® 327 (R327) and anti-viral formulation RECCE® 529 (R529), including the composition/method of manufacture, the use of R327 or R529 for the treatment of viruses having a lipid envelope or coat, influenza viruses, HIV, hepatitis, Ross River and herpes viruses, and the administration of R327 or R529 by oral, injection, inhalation and transdermal dose.
[Recce Pharmaceuticals, Ltd.] |
|
|
|
|
| March 19 – 21, 2023
Sitges, Spain |
|
|
|
|
|
| | The University of Edinburgh – Edinburgh, United Kingdom |
|
|
|
| | STEMCELL Technologies РSt. Egreve, Auvergne-Rh̫ne-Alpes, France |
|
|
|
| | Rutgers New Jersey Medical School – Newark, New York, United States |
|
|
|
| | Karolinska Institutet – Solna, Sweden |
|
|
|
| | Pfizer – Pearl River, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
